An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

NCT05622370 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Partial Seizure

Interventions

DRUG: Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)
DRUG: Brivaracetam sustained-release tablets 100mg
DRUG: Brivaracetam sustained-release tablets 50mg

Sponsor

Overseas Pharmaceuticals, Ltd.

Collaborators

[object Object]